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1. Introduction  
Dementia is a syndrome that can be caused by a number of progressive disorders that affect 
memory, thinking, behaviour and the ability to perform everyday activities, with increasing 
loss of function. Dementia mainly affects older people; after age 65, the likelihood of 
developing dementia roughly doubles every five years (Alzheimer’s Association, 2011; 
Wimo & Prince, 2010). Patients with dementia usually survive 7-10 years after onset of 
symptoms, placing a tremendous burden not only on caregivers, but also on society 
(Alzheimer’s Association, 2010; Wimo et al., 2010).  
Due to increasing life expectancy the number of people suffering from dementia will 
increase rapidly in both developed and developing countries. As a result, the management 
of dementia patients is now becoming one of the most important public health problems 
(Wimo et al, 2003). It is estimated that 24.3 million people have dementia today, with 4.6 
million new cases of dementia every year (one new case every 7 seconds). The number of 
people affected will double every 20 years to 81.1 million by 2040. Most people with 
dementia live in developing countries (60% in 2001, rising to 71% by 2040). Rates of increase 
are not uniform; numbers in developed countries are forecast to increase by 100% between 
2001 and 2040, but by more than 300% in India, China, and their south Asian and western 
Pacific neighbours; i.e. the rate of increase in numbers of people with dementia is predicted 
to be three to four times higher in developing areas than in developed regions (Ferri et al., 
2005). Hence, dementia is one of the most important public health problems. 
The syndrome of dementia may be caused by various underlying diseases, each 
characterised by a specific constellation of signs and symptoms in combination with a 
presumed underlying substrate of neuropathology. Alzheimer’s disease (AD) is the most 
prevalent cause of dementia. It is a neurodegenerative disorder, generally assumed to be 
caused by neuritic plaques and neurofibrillary tangles accumulating in the brain. The 
second most prevalent cause of dementia is vascular dementia (VaD), which may be caused 
by various types of vascular pathology in the brain, such as ‘‘large vessel’’- large territorial 
or strategical infarctions, and ‘‘small vessel’’- lacunes and white matter hyperintensities 
disease, (Van der Flier & Scheltens, 2005).  
Current data from developing countries suggest that age-adjusted dementia prevalence 






consistently low (1–3%) in India and sub-Saharan Africa (Kalaria et al., 2008). In 2000, 
prevalence data from 11 European population based studies were pooled to obtain stable 
estimates of prevalence of dementia in the elderly ( > 65 years); age standardised prevalence 
was 6.4% for dementia (all causes), 4.4% for AD, and 1.6% for VaD (Berr et al., 2005; Lobo et 
al., 2000). The ratio between AD and VaD was similar in most studies of US, Europe and 
Africa. Alzheimer’s disease is the most common etiology of dementia and accounts for 50-
70% of total dementia cases. The second most common etiology is vascular dementia and 
account for 20-30% of total dementia (Fratiglioni et al., 1999). 
Dementia syndrome develops over a long period of time characterized by progression from 
normal cognition defined as preclinical stage, through a transition phase of cognitive 
impairment defined as mild cognitive impairment- MCI, to full-scale dementia. Preventive 
strategies can be implemented before the onset of the process of dementia by eliminating or 
treating risk factors, as well as promoting protective factors (primary prevention). Secondary 
prevention relies on the identification of clinical or biological markers for disorders that lead to 
dementia in order to detect subjects early who will develop dementia within a few years. 
Tertiary prevention includes the identification of prognostic factors and the evaluation of the 
care provided to patients with dementia by comparing different care strategies in terms of 
specific individual and family outcomes (The Swedish Council SBU, 2008). 
In that context, these two common etiology of dementia, i.e. Alzheimer’s disease and 
vascular dementia have different characteristics, and there are diagnostic criteria for each of 
them. This article will focus on the difference between Alzheimer’s disease and vascular 
dementia in light of recent development of research in each field. 
2. Concepts of vascular dementia and Alzheimer’s disease – Diagnosis 
criteria 
2.1 Evolution of concepts  
Since the 1970s, the concept of vascular dementia (VaD), a type of dementia secondary to 
stroke and vascular disease, has been distinguished from the purely neurodegenerative 
form of dementia, (AD). Since then, many clinical, neuropsychological, radiologic, and 
pathologic criteria have been proposed in an attempt to distinguish these entities in order to 
identify a homogenous group of patients who supposedly all share a common specific 
underlying mechanism of dementia; hence, allowing design of mechanism-specific therapies 
for this homogenous group of patients. The Diagnostic and Statistical Manual (DSM) of the 
American Psychiatric Association is the most influential classification of mental disorders 
worldwide. The third edition of this manual (DSM-III), published in 1980, was considered to 
be a major step forward in establishing a reliable diagnostic system based on evidence. The 
DSM has been revised periodically as new data have emerged, the last major revision 
having been in 1994 (DSM-IV), and a minor one in 2000 (DSM-IV-TR). The DSM-IV offers 
guidelines for diagnosis of one type of primary degenerative dementia - dementia of 
Alzheimer type (DAT) – and one type of VaD - multi infarct dementia (MID), now called 
VaD (American Psychiatric Association, 1994, 2000). ICD-10 offers four main categories of 
dementia, in which DAT is subclassified with respect to early versus late onset, typical 
versus atypical clinical features, and pure or combined with VaD; and VaD is described in 
terms of type of onset and predominant involvement. IDC-10 recognized 6 subtypes of 
“vascular (formerly arteriosclerotic) dementia”, which includes such entities as “VaD of 
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acute onset”, “subcortical VaD”, “mixed cortical and subcortical VaD”, “other VaD” and 
“VaD unspecified” in addition to MID. Subcortical VaD with extensive diffuse 
demyelination and small focal infarctions was also referred to as “Binswanger’s 
encephalopathy” (World Health Organization, 1992). The state of California Alzheimer 
Disease Diagnostic and Treatment Center (ADDTC) proposed the first set of criteria for the 
diagnosis of ischemic vascular dementia (IVD) in 1992, describing probable, possible, and 
definite IVD, as well as mixed dementia. VaD was also defined in terms of brain imaging, 
thereby extending the concept to include MID, single stroke dementia and Binswanger’s 
disease (Chui et al., 1992). The criteria developed by the National Institute of Neurological 
Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences (AIREN) (Román et al., 1993), elaborated on the cause-
effect relationship between cerebrovascular disease and symptoms of dementia; with the 
goal of facilitating treatment and epidemiological research, it emphasized the need of 
clinical and neuroimaging criteria for early and specific diagnosis of probable, possible and 
definite VaD. The NINCDS-ADRDA work group for standardization of clinical criteria for 
diagnosis of AD (McKhann et al., 1984) recommended the terms “possible AD” and 
“probable AD” and “definite AD”, along with the pathologic criteria (Mirra et al., 1991). The 
introduction of MID was followed by the presentation of the Ischemic Score rating scale for 
differential diagnosis between AD and VaD (Hachinski et al., 1975). Differentiating among 
dementias presents many difficulties, especially at an early stage, and no single available 
diagnostic technique can solve all of these problems. The common clinical criteria (ICD-10, 
DSM-IV, ADDTC, NINDS-AIREN) for VaD are umbrella systems in that they do not 
consider the specific situation. Comparative studies show a lack of agreement among the 
systems; despite similarities, they identify different patients and patient groups. Not only do 
these differences affect prevalence and incidence estimates, but clinical management 
becomes more capricious. In order to promote the development of more effective 
pharmacological treatments and other improvements, the criteria systems need to be 
modified and made more specific. Thus, greater attention should be paid to vascular 
mechanisms and subtypes.  
2.2 The DSM-V neurocognitive disorders cluster 
In response to clinical and research developments since the publication of DSM-IV, the 
process to revise the classification for a DSM-V, to be published in 2012, started in 2006 with 
the establishment of a DSM-V Task Force, and a Work Group for neurocognitive disorders 
(Chair: Professor Dilip Jeste) in 2007. The draft proposed criteria from this Work Group was 
recently put on- line for general comments. The publication of DSM-V will have a major 
influence on the commonly used classification of neurocognitive disorders (Sachdev, 2010). 
Among the major changes in structure and criteria for dementia and related disorders were: 
the term dementia is replaced with the more descriptive “Major Neurocognitive Disorder” 
(NCD); the criteria are reworded to reflect a focus on decline from a previous level of 
performance; also, the requirement for a deficit in memory is removed to better 
accommodate NCD due to other non-Alzheimer etiologies (Blacker, 2010). The field is 
moving towards earlier detection of the diseases underlying dementia, such that the 
disorder can be recognized, and possibly treatment started, before the dementia stage, e.g., 






In other disorders, cognitive impairment may be static and not progress beyond the mild 
stage, but still be a focus for assessment and care. Hence, the category of Minor NCD 
(similar to Mild Cognitive Impairment) has been added given that this syndrome has 
become a major focus of research and clinical care (Ganguli, 2010). 
The definitions of Major and Minor NCD are based on the primary cognitive disturbance, 
with a requirement for both cognitive symptoms elicited from the subject or an informant or 
observed by the clinician, and quantifiable deficits on cognitive assessments. At the Minor 
level, the cognitive symptoms may involve greater difficulty performing cognitive tasks 
(rather than inability), and the deficits are typically in the range of 1-2 SD below age- and 
education-adjusted means of neuropsychological tests. At the Major level, the deficits are 
typically >2 SD below the mean. The distinction between Minor and Major also rests on the 
preservation or loss of independence. Specific etiologic subtypes will also have specific 
criteria cutting across Major and Minor NCD (Blacker, 2010). 
2.3 The new criteria for Alzheimer’s disease 
Criteria for the clinical diagnosis of Alzheimer’s disease (AD) were established in 1984 
(McKhann et al., 1984). Owing to clinical and research development, a broad consensus now 
exists that these criteria should be revised. The National Institute on Aging (NIA) and the 
Alzheimer’s Association sponsored a series of advisory round table meetings in 2009 whose 
purpose was to establish a process for revising diagnostic and research criteria for AD. Two 
notable differences from the AD criteria published in 1984 are incorporation of biomarkers 
of the underlying disease state and formalization of different stages of disease in the 
diagnostic criteria. The recommendation from these advisory meetings was that three 
separate work groups should be formed with each assigned the task of formulating 
diagnostic criteria for one phase of the disease: the dementia phase, the symptomatic pre-
dementia phase, and the asymptomatic preclinical phase of AD. A semantic and conceptual 
distinction is made between AD pathophysiological processes and clinically observable 
syndromes that result, whereas this distinction was blurred in the 1984 criteria. The new 
criteria for AD are presented in three documents. The core clinical criteria of the 
recommendations regarding AD dementia (McKhann et al., 2011) and MCI due to AD 
(Albert et al., 2011) are intended to guide diagnosis in the clinical setting. However, the 
recommendations of the preclinical AD workgroup (Sperling et al., 2011) are intended 
purely for research purposes. 
2.4 Vascular dementia nosology 
2.4.1 Historical overview 
Modern history of dementia began in 1910 with Emil Kraepelin’s influential textbook 
Psychiatrie. His work was based on clinical pathology studies by Otto Binswanger and Alois 
Alzheimer. The brain lesions that were assumed to be responsible for dementia consisted of 
arteriosclerotic brain atrophy (characterized by multiple lacunar strokes and “ état criblé ” - 
dilated perivascular spaces - associated with arteriosclerosis of small and large blood 
vessels), senile cortical atrophy (granular atrophy and laminar necrosis), periventricular 
white matter atrophy (Binswanger’s disease), perivascular gliosis (wedgeshaped lesions 
resulting from severe stenosis of a large vessel), arteriosclerotic hemispheric foci 
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(predisposing for “dementia postapoplexia”) and the combined forms of dementia. In 
practice, arteriosclerotic dementia was synonymous with senile dementia. Successively 
impaired blood flow was thought to lead to neuron death (Roman, 1999). In the mid 1970s, 
AD was first regarded as the main cause of brain atrophy and dementia. The notion of 
chronic brain ischemia as an explanation of dementia was abandoned. Now vascular lesions 
in patients with dementia are receiving growing attention. Stroke-related dementia is 
increasingly in the spotlight, as is subcortical VaD with white matter damage and lacunae, 
regarded by some as the most common form of VaD (Roman et al., 2002). 
2.4.2 Heterogeneity of vascular dementia 
The increased percentage of elderly in the general population, along with changes in the 
cerebrovascular disease panorama in terms of reduced stroke mortality, has led to 
reevaluation and renewal in this field. Instead of using simplified disease categories, the 
assertion was that vascular mechanisms leading to cognitive impairment should form the 
basis of disease classification (Gorelick & Mangone, 1991; Hachinski, 1990). Among such 
vascular mechanisms are thromboembolism, vessel wall damage (Atherosclerosis, 
hyalinosis, amyloid angiopathy), cerebrovascular insufficiency (Disturbance of systemic 
circulation, vascular anatomy of the brain, disturbed regulation of cerebral blood flow), 
hyperviscosity, bleeding. Because several such mechanisms exist (Parnetti et al., 1994; 
Wallin & Blennow, 1993), there are also several types of VaD (Chui, 1989; Rockwood et al., 
1999; Roman et al., 2002). 
3. Mixed-type dementia 
Mixed dementia is diagnosed when patients have evidence of Alzheimer dementia and 
cerebrovascular disease, either clinically or based on neuroimaging evidence of ischemic 
lesions. Growing evidence indicates that vascular dementia and Alzheimer dementia often 
coexist, especially in older patients with dementia (Langa et al., 2004). The occurrence of 
vascular risk factors and diseases are regarded as exclusion criteria for the diagnosis of AD. 
However, longitudinal epidemiological studies have shown that hypertension, diabetes, 
atrial fibrillation, and smoking are risk factors for AD as well as VaD. Ischemic processes 
have proven not only to co-exist with AD, but to potentiate its development (Cacabelos et 
al., 2003; Ravona-Springer et al., 2003; Skoog & Gustafson, 2003). Autopsy studies have 
shown an association between Alzheimer disease and vascular lesions (Snowdon et al., 
1997). Toncosco et al. (2008) report autopsy findings from the Baltimore Longitudinal Aging 
Study among 122 men and 57 Women; macroscopic and microscopic infarcts contributed 
equally to dementia risk, and hemispheral infarcts, whether silent or clinically manifest, 
alone or in conjunction with AD pathology accounted for 35% of dementia cases. The 
findings support a synergism between AD and vascular pathology and the importance of 
burden and location of infarcts. 
Vascular pathology in the aging brain and AD includes ischemic infarcts, lacunes, cerebral 
hemorrhages, white matter lesions, blood-brain barrier (BBB) dysfunction, cerebral amyloid 
angiopathy (CAA), and microvascular degeneration (Jellinger & Attems, 2003). These 
pathologies are commonly seen in various vascular diseases and can contribute to cognitive 






executive functioning (Jellinger, 2007). The OPTIMA project showed that cerebrovascular 
disease impaired cognitive performance in early phases of AD but not later in the course of 
the disease (Esiri et al., 1999). At the same grade of dementia, fewer Alzheimer’s lesions 
were required in patients who had cerebrovascular damage (Zekry et al., 2002a). Another 
study reported that the combination of Alzheimer’s disease and vascular pathology was 
common in patients with cognitive impairment, however, no threshold effects for the 
various changes could be found (Neuropathology group - MRC CFAS, 2001). 
Recent evidence from epidemiological, clinical, pathological, and Neuroimaging studies 
implicates neurovascular dysfunction as an integral part of AD. Data from these studies 
reveal a distinct association between vascular risk factors and AD (Dickstein et al., 2010). 
These include hypertension (Kivipelto et al., 2001), total cholesterol, type II diabetes mellitus 
(Ott et al., 1999), hypotension, smoking (Ott et al., 1998) and oxidative stress (Zhu et al., 
2007). Furthermore, dysfunction of the endothelial cells that compose the BBB has also been 
demonstrated and correlates with AD severity (Dede et al., 2007). The degree to which these 
factors contribute to AD may be influenced by genetic factors such as apolipoprotein E, 
which has a role in both AD and vascular disease. Ischemia via vasoactive effects of 
amyloid, impaired blood flow, reduced metabolism, inflammatory mechanisms and changes 
in the blood-brain barrier are among the factors that have been regarded as the genesis of 
vascular tissue damage in AD. Some authors have even claimed that AD is primarily 
microvascular, for which degeneration of the capillaries in the hippocampus and other brain 
regions, including secondary neuronal hypometabolism, is the central pathophysiological 
chain of events (De la Torre, 2002). 
Identifying patients with AD and concurrent cerebrovascular disease is not easy when the 
patient lacks markers for AD. That may be one reason for the rate of mixed dementia having 
been underestimated (Kalaria & Ballard, 1999). According to a relatively current review of 
clinical neuropathological studies, mixed dementia accounts for 20 to 40% of dementia cases 
(Korczyn, 2002; Zekry et al., 2002b). Alzheimer’s disease pathology occurs frequently in 
asymptomatic elderly individuals and clinical dementia is more likely to be present when 
AD is accompanied by strokes and cerebrovascular related brain changes (Riekse et al., 
2004). The cognitive consequences of vascular lesions are cumulative. So VaD and perhaps 
also mixed dementia are potentially preventable if vascular risk factors are controlled and 
strokes do not recur. To better guide the treatment of patients with mixed dementia, future 
studies should similarly broaden their criteria to include patients with evidence for mixed 
causes of dementia, rather than identifying only pure AD and VaD (Langa et al., 2004). 
4. Vascular cognitive disorders – Vascular cognitive impairment (VCI) 
The term “vascular cognitive disorder” was proposed by Sachdev (1999) to define vascular 
cognitive deficits of sufficient severity to meet criteria for a diagnosable disorder. It was 
intended as an umbrella term to include the spectrum of impairment from mild vascular 
cognitive impairment to vascular dementia (Roman et al., 2002). Vascular cognitive 
impairment (VCI)) is the modern term related to vascular burden of the brain, reflecting all 
encompassing effects of cerebrovascular disease on cognition. VCI include all levels of 
cognitive decline from mild deficits in one or more cognitive domains to a broad dementia-
like syndrome. VCI incorporates the complex interactions between vascular risk factors, 
cerebrovascular disease etiologies and cellular changes within the brain and cognition 
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(Chui, 2006; Erkinjuntti & Gauthier, 2009). The extent to which cognitive disturbance is 
progressive or non progressive is important to delineate, because it suggests initiation of a 
process for development of dementia, or instead a cognitive residual syndrome.  
Vascular cognitive impairment (VCI) has continued to evolve over the past year. Much of 
the data has been confirmatory with further work on risk factors, silent strokes, 
leukoaraiosis and lesion volume and location. The importance of the interaction between 
cerebrovascular disease and other causes of cognitive impairment, most importantly 
Alzheimer disease (AD) remains a prominent theme (Bowler & Gorelick, 2009). 
From a neuropathologic perspective, once irreversible parenchymal injury has occurred, 
there are downstream and retrograde effects in the central nervous system that result from 
the insult - as a function of Wallerian, trans-synaptic and other types of degeneration which 
almost certainly affect subsequent neurobehavioral morbidity (O'Brien et al., 2003; Vinters et 
al., 2000). Subcortical axonal injury and loss might be key elements in VaD pathogenesis and 
progression (Medana & Esiri, 2003). The identity of the neuropathologic substrates of 
leukoaraiosis, which also affects subcortical white matter, is still controversial, but might 
include apoptosis of oligodendroglia (Brown et al., 2000). 
VCI represents a paradigm shift from vascular dementia towards a much earlier state, 
characterized most commonly by a subcortical frontal and executive pattern of cognitive 
impairment, as opposed to the previous concept of an Alzheimer-based amnestic syndrome. 
The principal object of VCI as a concept is to facilitate case identification in this early stage, 
because progression may be preventable through modification of vascular risk factors 
(Bowler, 2007). Data on VCI are still relatively limited, because much of the research done 
over the past two decades has been based now on the outdated criteria for vascular 
dementia. To help resolve this, the National Institute of Neurological Disorders and Stroke 
and Canadian Stroke Network have recently published comprehensive guidelines for 
research studies in VCI (Hachinski et al., 2006). 
On the other hand, VCI is an evolving concept, and as our understanding grows, new 
questions arise (Chui, 2006; Merino, 2008). The development of a single, uniform set of 
criteria that apply to all subtypes of VCI has clearly been challenging, and some experts 
have recommended that separate criteria be developed for certain subtypes (Roman et al., 
2002). (To be discussed in the next section). 
5. Mild cognitive impairment (MCI) – Vascular cognitive impairment no 
dementia (VCIND) 
Age-related cognitive change can be placed along a continuum from normal to severely 
demented, with intermediate stages of cognitive decline. To date, there is no consensus on 
where boundaries between disease and non-disease lie. Rather than a strict dichotomisation, 
the determination of impairment may instead be based on the likelihood or probability that 
ageing is not occurring in accordance with normative expectations (Stephan et al., 2009). 
5.1 Mild cognitive impairment 
The term mild cognitive impairment (MCI) broadly defines an intermediate state of 






be predictive of dementia, primarily Alzheimer’s disease. Various definitions have been 
proposed in the literature, each with differences in focus- age associated change versus 
pathological decline, and diagnostic criteria - memory versus non-memory impairment, 
(Morris, 2006; Winblad et al., 2004).  
As a possible tool for identifying individuals at increased risk of dementia, MCI is an 
important concept. Indeed, in clinical samples, individuals with a case diagnosis of the 
anmestic subtype of MCI (a-MCI) have been found to progress to dementia at a rate of 10% 
to 15% per year compared with a progression rate of only 1% to 2% in normal controls 
(Bruscoli & Lovestone, 2004; Petersen et al., 2001). In contrast, in the general population, the 
positive predictive validity of a-MCI is poor (Matthews et al., 2008). Many incident 
dementia cases are found to be excluded from an a-MCI case diagnosis, and of persons with 
a-MCI, many remain stable or revert to normal cognitive status at follow-up (Matthews et 
al., 2007). These findings are consistent across all MCI definitions-amnestic versus 
nonamnestic, and single versus multiple domains MCI- (Matthews et al., 2008).  
No MCI criteria can be recommended for population screening of individuals at high 
dementia risk (Stephan et al., 2008). Poor predictability possibly results from limitations in 
case findings due to a lack of clinical judgement and inflexibility in operationalisation of 
criteria when a diagnosis of MCI is made outside the clinical setting. However, it has been 
suggested that MCI predictability may be improved through consideration of the 
underlying pathogenesis of cognitive decline (Tervo et al., 2004). Subclassification of MCI 
with and without co-morbid vascular disease may therefore be important for discriminating 
individuals at high versus low dementia risk in the general population (Stephan et al., 2009). 
To better identify the link between vascular disease and cognitive impairment, the term 
vascular cognitive impairment (VCI) was introduced (Bowler, 2007; Bowler & Hachinski, 
1995; Román et al., 2004; Selnes & Vinters, 2006). 
5.2 Vascular cognitive impairment no dementia 
As already mentioned, vascular cognitive impairment refers to cognitive decline attributable 
to vascular disease. However, unlike mild cognitive impairment which is a narrow term 
capturing a pre-clinical form of dementia, vascular cognitive impairment encompasses 
individuals affected with any degree of cognitive decline caused by or associated with 
vascular disease and its risk factors. As such, the level of impairment in vascular cognitive 
impairment ranges in severity from mild cognitive impairment to vascular dementia or 
mixed vascular dementia, in which cerebrovascular and AD pathologies co-occur. Calls for 
more specific staging have recently led to further subclassification of vascular cognitive 
impairment to capture vascular disease-related impairment not fulfilling criteria for 
dementia. This stage is defined using the term vascular cognitive impairment no dementia 
(VCIND). Whether within VCIND there is a state predictive of dementia is largely 
unknown. Where longitudinal outcome across the spectrum of vascular cognitive 
impairment has been investigated, progression is not always clinical -that is, 
decline/dementia, with many cases improving or remaining stable at follow-up (Hsiung, 
2006; Rockwood et al., 2007; Wentzel et al., 2001). Predictive ability may depend on the 
nature of the vascular disturbance in addition to methodological factors- case description, 
sample and nature of cognitive impairment.  
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As with MCI, terminology and diagnostic criteria for VCIND have not been harmonised, 
making cross-study comparison of disease outcomes difficult. Generally, the differential 
diagnosis between MCI and VCIND is clinical and based on the distinction between 
Alzheimer’s disease and Vascular dementia. Alzheimer disease is characterised by a steady 
and progressive loss of memory and cognitive faculties, including language deterioration, 
impaired visuospatial skills and poor judgement. In contrast, the disease course of Vascular 
dementia is highly variable, generally following a stepwise pattern of decline and 
fluctuating course. For a diagnosis of Vascular dementia , it is recommended that 
radiographic features of vascular disease, including evidence of an ischaemic lesion, white 
matter hyperintensities and/or hypometabolism, be confirmed (American Psychiatric 
Association, 2000). Frequently both pathologies co-occur (Neuropathology group- MRC 
CFAS, 2001; Snowdon et al., 1997). AD and VaD may share associated risk factors (stroke, 
arterial hypertension, increasing age and low educational attainment), structural changes, 
neuropathological profiles (white matter lesions and apoptosis) and neurochemical changes 
(that is, in the cholinergic system) (Small et al., 2002). In older people, multi-morbidity is 
common and a strict dichotomisation between degenerative and vascular dementing 
disorders at both pre-clinical and dementia stages is difficult to undertake, possibly artificial 
and perhaps not the most useful approach. 
5.3 Cognitive, neuroimaging and neuropathological profiles of MCI and VCIND 
5.3.1 Cognitive profile 
Neuropsychological studies have identified attentional executive deficits and psychomotor 
slowing, with relatively preserved language and recognition memory in individuals with 
vascular disease (Hachinski et al., 2006). However, not all studies agree on the importance of 
each cognitive domain and no single deficit or pattern of deficits as yet accurately signals an 
underlying vascular cause (Graham at al., 2004). For example, cognitive impairment as a 
consequence of stroke would likely depend on not only timing and the anatomical location 
of the stroke, but also the laterality, severity and extent of the lesion. 
The focus of MCI is predominantly impaired memory, but deficits in other cognitive 
domains will also be observed when, by definition, they are also included. Subdivisions 
between different cognitive subtypes of MCI, amnestic versus nonamnestic, and single 
versus multi-domain, have implications for inference about aetiology and outcomes. Indeed, 
while a-MCI (Petersen, 2007) is thought to be a precursor of AD, nonamnestic subtypes of 
MCI have been found to identify individuals at high risk of both AD and VaD (Rasquin et 
al., 2005). 
Where the cognitive profile of individuals with MCI and comorbid vascular disease has 
been compared with that of individuals with MCI and no vascular disease, group 
differences have been reported in some (Hayden et al., 2005; Nordlund et al., 2007), but not 
all studies (Loewenstein et al., 2006). Where differences have been observed, the MCI 
vascular group shows more extensive cognitive impairment primarily in speed, attention 
and executive function, (Nordlund et al., 2007) consistent with the general pattern of 
cognitive difficulties resulting from vascular disease alone (Román et al., 2004). 
The specific type of cognitive impairment associated with vascular disease needs to be 






observational assessment of cognition in the context of vascular disease (that is, memory 
versus non-memory domains) need to be identified in order to facilitate the development of 
diagnostic criteria for cognitive decline in the presence (VCIND) versus the absence (MCI) of 
vascular disease (Stephan et al., 2009).  
5.3.2 Neuroimaging profile 
Neuroimaging in VCIND shows a pattern of vascular lesions that are similar to, but less 
severe than, changes observed in VaD (Meyer et al., 2007). Pathology includes evidence of 
leukoaraiosis and white matter infarction (Vermeer et al., 2007), with mild hippocampal and 
entorhinal cortex atrophy relative to the level seen in MCI /AD (Meyer et al., 2007). In 
contrast, neuroimaging in MCI generally shows a pattern of changes similar to that 
observed in AD, namely temporal and hippocampal atrophy, reduction in whole-brain 
glucose metabolism and white matter degeneration, including hyperintensities and white 
matter lesions identified using diffusion tensor imaging (Assaf et al., 2008; Devanand et al., 
2007; Johnson et al., 2006). 
The severity and type of lesions required for a diagnosis of MCI and VCIND remain 
controversial. Vascular disease and its risks are associated with brain changes but the 
clinical relevance of such changes in the prediction of cognitive decline and dementia 
progression remains uncertain. Isolating unique disease effects from the effects of ageing 
and other risk factors (that is, genetic susceptibility) will be important in determining 
cellular/ molecular /functional vulnerability as a consequence of vascular disease as well as 
establishing with accuracy those changes that distinguish who will and will not develop 
cognitive decline and subsequent dementia (Stephan et al., 2009). 
5.3.3 Neuropathology profile 
MCI cases generally show an increase in neurofibrillary tangle pathology in memory-related 
cortical regions, including the entorhinal cortex, fusiform gyrus and temporal pole (Bennett 
et al., 2005). These changes are thought to represent one of the earliest pathological 
substrates of this condition and have been taken to suggest that many MCI cases are early or 
prodromal AD (Morris et al., 2001). 
Whether there is a consistent neuropathological profile across the spectrum of vascular 
causes and severity levels of VCI is unknown but seems unlikely. Indeed, VCI is a 
multifactor disorder related to a wide variety of lesions and causes, and as such the 
pathological profile, similarly to the psychological and radiological profiles, would be 
expected to be heterogeneous. In autopsy studies, an increased prevalence of cerebral 
vascular pathology has been found in individuals with stroke, diabetes mellitus 
(Arvanitakis et al., 2006), angina with comorbid dementia (Andin et al., 2005) and 
hypertension (Petrovitch et al., 2000). Pathological features have included large- and small-
vessel disease, gliosis, microvascular brain damage (severe cribriform change), white matter 
damage, microinfarction and haemorrhage (Kalaria et al., 2004). The profile of pathology 
across the different vascular disease factors is heterogeneous and the significance of such 
changes in the development of cognitive impairment is not known. Across the spectrum of 
age-associated brain changes, no neuropathological profile yet exists that reliably 
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distinguishes impairment of different severity levels and causes. In the general population, 
currently identifiable pathological features have not been found to correlate well with 
observed clinical and cognitive profiles: many non-demented healthy controls also show 
evidence of pathological brain changes associated with both AD and VaD (Jagust et al., 
2008). Techniques that better characterise the impact of vascular disease on brain structure 
and more sensitive measures for accurately staging cognitive status which incorporate 
known risk factors are needed for diagnostic differentiation between an at-risk and a “not 
at-risk” brain. However, as with AD, expecting neuropathology to be a gold standard at any 
given age for the diagnosis of VCI is an oversimplification (Brayne, 1993). 
6. Disease manifestations of vascular dementia 
6.1 Symptom profile 
VaD is an heterogeneous disease group with symptoms that vary according to the type of 
tissue damage, location, size and number of lesions. The main subtypes of VaD included 
in current classifications are cortical VaD (or MID) and subcortical vascular dementia (or 
small vessel disease related dementia) (Brun, 1994; Cummings, 1994; Roman et al., 1993; 
Wallin et al., 2003). The clinical presentation of cortical and subcortical forms of VaD show 
remarkable differences. Large vessel occlusions resulting in large cortical infarcts produce 
cognitive and other deficits that depend on the location of the infarcts, while subcortical 
vascular dementia may have a relatively characteristic neuropsychological profile that 
includes early impairment of attention and executive function, with slowing of motor 
performance and information processing (O'Brien et al., 2003; Roman et al, 2002; Roman & 
Royall, 1999). 
Selected original publications show that executive dysfunction was the key factor 
underlying functional impairment (Boyle et al., 2002). Disturbances in frontal lobe functions 
were found to be more pronounced in patients with VaD than AD. Memory disturbances 
proved to be less pronounced early in the course of the disease than for AD. However, once 
the disease had progressed to a moderately severe level, the disturbances were just as 
pronounced as in AD. Executive dysfunction may also appear in AD patients, but it more 
resembles attention deficit disorder. In VaD, executive dysfunction more involves a 
fundamental inability to work out strategies and carry out tasks (Cannata et al., 2002). To 
obtain a greater understanding of the clinical manifestations, many authors have 
recommended a subtype classification of VaD (Chui, 1989; Erkinjuntti, 1987). 
6.2 Small vessel disease and subcortical vascular dementia 
Subcortical vascular dementia is the current terminology for severe cognitive impairment 
associated with small vessel disease (Erkinjuntti et al., 2000). Given its strong vascular 
component, it is believed to be more preventable than dementia of the Alzheimer’s type. 
Subcortical vascular dementia results from lacunar infarcts or multiple microinfarcts in the 
basal ganglia, thalamus, brainstem, and focal and diffuse ischaemic white matter lesions 
(WMLs), and are associated with more than 50% of the VaD cases (Kalaria et al., 2004; 
Kalaria & Erkinjuntti, 2006). It represents the most homogeneous and probably most 






Clinically, subcortical vascular dementia is characterised by pure motor hemiparesis, bulbar 
signs and dysarthria, gait disorder, variable depressive illness, emotional lability, and 
deficits in executive functioning; however, these focal neurological signs are often subtle. 
Upon imaging, patients have multiple lacunes and extensive WMLs and often reveal clinical 
history of “prolonged transient ischemic attack” (TIA) or “multiple TIAs” which mostly are 
small strokes without residual symptoms and only mild focal findings (e.g. reflex 
asymmetry, gait disturbance). This supports the importance of neuroimaging requirements 
in the criteria (Erkinjuntti et al., 2000). 
Most studies on stroke associated with small vessel disease focus on motor impairment and 
mortality. Few studies have investigated the frequency of differering severity levels of 
cognitive impairment. Mok et al. (2004) evaluated consecutive patients with or without 
previous stroke who were admitted to the acute stroke unit. In this hospital based study, 
half of the patients with stroke associated with small vessel disease had varying severity of 
cognitive symptoms 3 months after stroke. Pre-stroke cognitive decline and previous stroke 
predicted severe cognitive impairment. Their findings highlight the importance of cognitive 
impairment, and in particular, executive dysfunction, in affecting the functional outcome of 
patients with stroke associated with small vessel disease.  
The early cognitive syndrome of subcortical vascular dementia is characterized by a 
dysexecutive syndrome with slowed information processing, usually mild memory deficit 
and behavioural symptoms (Kramer et al., 2002; Roman et al., 2002). The dysexecutive 
syndrome includes impairment in goal formulation, initiation, planning, organising, 
sequencing, executing, set-shifting and set-maintenance, as well as in abstraction (Desmond 
et al., 1999). The memory deficit is usually milder than in AD, and is specified by impaired 
recall, relative intact recognition, less severe forgetting and better benefit from cues. 
Episodic memory may be relatively spared, compared with AD.There is more learning 
impairment that can be partially corrected by providing salient cues to encourage learning 
and promote recognition. Therefore, memory deficits in VaD appear to be caused by 
problems in retrieval of information (Sachdev et al., 2004); in turn, memory retrieval deficits 
are due to aberrant frontal and subcortical mechanisms. In contrast, in AD involvement of 
the hippocampus by neurofibrillary tangles prevents storage of new information causing 
amnesic mild cognitive impairment. 
Eventually, cognitive impairment in small vessel disease may progress from mild to severe 
cognitive impairment. Behavioural and psychological symptoms in subcortical vascular 
dementia include depression, personality change, emotional lability, apathy, incontinence, 
as well as inertia, emotional bluntness and psychomotor retardation. These may include 
greater tendencies of aggression and agitation. Such symptomatology is attributed to 
damage to the prefrontal subcortical circuits (Cummings, 1993). 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL), is an example of familial subcortical vascular dementia that presents with 
recurrent subcortical strokes and slowly progressing course leading to cognitive impairment 
and dementia. This disorder is a rare cause of VaD, but is much more common than familial 
AD (Opherk et al., 2004).   
Patients with subcortical VaD had more pronounced impairment than those with AD in 
their ability to deal with complex information, formulate strategies and exercise self-control. 
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The executive dysfunction of AD patients was mainly associated with attention deficit 
disorder and impaired working memory (Cannata et al., 2002). Patients with subcortical 
VaD have shown less pronounced episodic memory impairment, but more depressive 
symptomatology and greater variability in progress speed, than those with AD (Bennett et 
al., 1994). It has been suggested that patients with subcortical microvascular disease are 
the ones who later develop dementia that shows signs of mild cognitive impairment in the 
early phases of the disease (Meyer et al., 2002). A disturbance in the executive control 
function leads to global impairment of the ability to engage in everyday social activities 
and work, as well as the development of dementia. In addition to being a characteristic 
disturbance in VaD, there is much to suggest that executive dysfunction is the 
determining component in the dementia syndrome itself. Changes found by magnetic 
resonance imaging (MRI) in the subcortical area of patients with VaD showed an 
association with impairment of executive and psychomotor, but not global cognitive, 
capacity (Cohen et al., 2002; Libon et al., 2004).  
6.3 Stroke 
One way to obtain more specific information about VaD is to study cognitive ability in the 
course of the disease following an established stroke episode. In their recently published 
review, Leys et al. (2005) and Henon et al. (2006) summarized the previous studies that 
explored the impact of stroke on the risk of poststroke dementia. According to these 
studies, stroke increases the risk of dementia, with prevalence rates ranging from 6% to 
32% within 3 months to 1 year after stroke, depending on the composition of the patient 
group and the choice of criteria for the dementia syndrome; and incidence rates of new-
onset dementia after stroke ranging from 10% to 24% within 3 years and 15% to 33.3% 
within 5 years (Censori et al., 1996; Desmond et al., 2000; Kokmen et al., 1996; Tatemichi et 
al., 1992). 
Studies that have examined the role of prestroke cognitive decline in the development of 
poststroke dementia have reported varying results. Pohjasvaara et al. (1998) found no 
difference in the proportion of demented and nondemented stroke patients with prestroke 
cognitive decline. However, Pohjasvaara et al. (1999) later reported that prestroke 
cognitive was positively correlated with poststroke cognitive decline. Barba et al. (2000) in 
a series of 251 consecutive unselected stroke patients found that 30% demonstrated 
dementia at 3-month follow up; and 10% had demonstrated dementia before the stroke. 
Reitz et al. (2008) in a prospective population-based study, with a mean follow-up time of 
6.3 years between first assessment of cognitive function at baseline and time of incident 
first stroke, in which the slope of cognitive performance before stroke was also taken into 
account, and which had a nearly complete follow-up with respect to dementia, does not 
suggest that the prestroke level of cognitive function is a major determinant of the effect 
of stroke on the risk of poststroke dementia; an incident stroke doubled the risk of 
subsequent dementia independent of prestroke level of cognitive function and prestroke 
rate of cognitive decline. This finding contradicts previous studies reporting a higher risk 
of poststroke dementia in persons with prestroke cognitive impairment compared with 
persons with normal cognition before stroke (Gamaldo et al., 2006; Mok et al., 2004). In 
investigating patients during the acute phase, Henon et al. found signs of pre-stroke 






poststroke dementia in persons with prestroke mild cognitive impairment. Barba et al. 
(2000) commented that the frequency of post stroke dementia depends on various factors 
such as the exclusion of hemorrhage or recurrent stroke, age range, length of follow-up, 
and diagnostic criteria. Srikanth et al. (2006) in the first prospective data on long-term 
cognitive transitions in a population-based first-ever stroke cohort, found that stroke 
recurrence was associated with an increased rate of long-term global cognitive decline 
after a first-ever stroke; stroke recurrence, early poststroke cognitive impairment, and 
increasing age were independently associated with diagnosis of new clinical dementia 
two years after a first-ever stroke.  
The influence of the location of the vascular lesion in the development of dementia remains 
to be determined. A role of the left hemisphere has been suggested (Lin et al., 2003; Zhou et 
al., 2004). Poststroke dementia was also found to be more frequent in patients with a 
hemispheric stroke compared to brainstem/posterior fossa lesions and in patients with a 
pooled anterior/posterior cerebral artery stroke compared to other locations (Desmond et 
al., 2000). Many studies did not find any relationship between stroke location and risk of 
poststroke dementia (Ivan et al., 2004; Madureira et al., 2001; Rasquin et al., 2004).  
Strategic infarction dementia is sometimes characterized as a special variety of post-stroke 
dementia. Isolated bilateral infarctions in the hippocampus can lead to dementia, but 
milder cognitive disturbances are more common. Bilateral thalamic, unilateral thalamic 
and basal frontal infarctions, as well as infarctions in the angular gyrus, non-dominant 
parietotemporal region and dominant hemisphere, are other strategically localized 
infarctions that reportedly cause dementia (Schmahmann, 2003). In addition to memory 
impairment, bilateral thalamic lesions yield apathy, attention deficit, and disturbances in 
wakefulness. Thus, involvement of the thalamus and bordering brain areas is often found. 
Effects on the extensive reciprocal thalamus-frontal and frontal reticular nerve 
connections may explain the discrepancy between the relatively limited lesions and the 
extensive symptomatology. Strategic infarction dementia has been called into question as 
a disease entity, given that the influence of other lesions is generally ignored (Pantoni et 
al., 2001). Stroke cause, vascular risk factors, hypoxic-ischemic disorders, radiological data 
of silent infarcts, cerebral atrophy, white matter changes also play a role in the 
development of poststroke dementia (Reviewed, Henon et al., 2006). The variation in 
cognitive status prior to the stroke episode and the development of cognitive dysfunction 
after stroke, as well as the variation of stroke-related and lesion-related characteristics that 
contribute to the development of dementia, suggest that post-stroke dementia is a 
heterogeneous condition for which factors other than the infarction formation itself are of 
importance. 
7. Biomarkers 
One of the most important goals of current research in AD is to develop and validate 
biomarkers, which can detect at an early stage individuals who are likely to develop AD. 
Important advance in this field have been made recently by the workgroup under the 
auspice of the National Institute on Aging and the Alzheimer’s Association (Sperling et al., 
2011). Referring to evidence of the underlying brain disease process as AD-
pathophysiological process (AD-P), a biomarker model - solely intended for research 
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purposes at this time - adapted from the original graph proposed by Jack et al. (2010) has 
been recently proposed in which the most widely validated biomarkers of AD-P become 
abnormal and likewise reach a ceiling in an ordered manner. This biomarker model parallels 
the hypothetical pathophysiological sequence of AD, and is particularly relevant to tracking 
the preclinical stages of AD ( Sperling et al., 2011). Biomarkers of brain Abeta amyloidosis 
include reductions in CSF Abeta 42 and increased amyloid tracer retention on positron 
emission tomography (PET) imaging. Elevated CSF tau is not specific to AD and is thought 
to be a biomarker of neuronal injury. Decreased fluorodeoxyglucose 18F (FDG) uptake on 
PET with a temporoparietal pattern of hypometabolism is a biomarker of AD-related 
synaptic dysfunction. Brain atrophy on structural magnetic resonance imaging (MRI) in a 
characteristic pattern involving the medial temporal lobes, paralimbic and temporoparietal 
cortices is a biomarker of AD-related neurodegeneration. Although solely intended for 
research purposes at this time, and pending the translation of research data into clinical 
practice, this biomarkers model represent an important step forward to advance the study of 
preclinical AD. Importantly, Lo et al. (2011) reported the result of a longitudinal study; a 
total of 819 research participants (229 with normal cognition, 397 with MCI, and 193 with 
AD) were enrolled for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) from 59 
study sites in the United States and Canada during the period from 2005 to 2007. The 
authors concluded that trajectories of Abeta 42 level in CSF, FDG uptake, and hippocampal 
volume vary across different cognitive stages. The longitudinal patterns support a 
hypothetical sequence of AD pathology in which amyloid deposition is an early event 
before hypometabolism or hippocampal atrophy, suggesting that biomarker prediction for 
cognitive change is stage dependent. 
For VaD, anatomical brain imaging helps determine the subtypes of VaD (hemorrhage 
versus ischemia, cortical versus subcortical, strategic infarction versus multi-infarction, large 
vessel disease versus small vessel disease) and thereby enhances our knowledge of vascular 
disease processes. Anatomical brain imaging has played a particularly large role in 
demonstrating small vessel-related white matter changes, evidence of leukoaraiosis and 
white matter infarction, with mild hippocampal and entorhinal cortex atrophy relative to 
the level seen in AD (Vermeer et al., 2007). Studies of neurochemical markers for VaD and 
its subtypes are considerably fewer than those on patients with AD. After acute ischemic 
stroke the CSF tau protein level is normal for one or two days, after which it increases and 
peaks after 2–3 weeks. The effect then subsides, and the values normalize after 3–4 months 
(Hesse et al., 2000). Several studies have shown a significant increase of phosphorylated tau 
in the fluid of AD patients, while the levels are normal in VaD patients (Blennow & 
Vanmechelen, 2003). Impaired BBB function occurs in patients with VaD, particularly 
subcortical VaD (Wallin et al., 2000). The impaired function probably reflects disorders in 
the arterioles, although the capillary level may also be compromised. Neurofilament, 
another cytoskeletal component, is concentrated in large myelinized neurons. The greatly 
increased neurofilament light subunit (NFL) in the CSF that has been found in patients with 
subcortical VaD has been associated with the presence of white matter changes ( Wallin et 
al., 2001); while CSF-NFL has been shown to be normal in patients with pure AD. 
Knowledge of neurochemical markers may also be important to understanding mixed 







The dominant view in the literature is that the symptom profile for vascular dementia 
differs from that of Alzheimer’s disease. Vascular dementia is characterized by mental 
slowness; impaired initiative, planning, and executive function impairment; personality 
changes; and gait disorders. Thus, methodological advances aimed at identifying and 
measuring the severity of the cardinal symptoms of mental slowness and executive 
dysfunction and better clinical criteria, are needed for vascular dementia to help us reliably 
distinguish it from Alzheimer’s disease.  
Greater attention should be paid to vascular mechanisms and subtypes. The few studies that 
have attempted to consider the full range of cerebrovascular lesions have found them to be 
common, particularly the subcortical, small vessel disease and white matter damage that 
increasingly appears to be among the key factors underlying the origin of vascular 
dementia. Further studies are needed to identify the pathological changes that are most 
important in the disease and as a result, neuropathological criteria and examination 
methods need to be specified and standardized. Anatomic brain imaging is a good deal 
more reliable in helping to identify vascular lesions than Alzheimer’s lesions, which is still 
under ongoing screening. The clinical criteria systems need to be modified and made more 
specific in the vascular dementia field.  
Although much remains to be done, the ongoing process of revision of clinical criteria, the 
refinement of neuropathologic studies, the progress in biomarkers development with 
disease stage specificity including the preclinical one; along with identification, validation 
and refinement of predictors of cognitive decline and dementia, will pave the way for a very 
promising and hopeful future, in the prevention, treatment and management of Alzheimer’s 
disease and vascular dementia. Earliest stage interventions may be the most efficacious. 
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